These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17555450)

  • 1. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
    Curtis CE; Grand FH; Musto P; Clark A; Murphy J; Perla G; Minervini MM; Stewart J; Reiter A; Cross NC
    Br J Haematol; 2007 Jul; 138(1):77-81. PubMed ID: 17555450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
    Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
    Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC
    Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
    Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
    Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
    Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
    Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
    [No Abstract]   [Full Text] [Related]  

  • 7. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
    Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
    Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
    Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.
    Trempat P; Villalva C; Laurent G; Armstrong F; Delsol G; Dastugue N; Brousset P
    Oncogene; 2003 Aug; 22(36):5702-6. PubMed ID: 12944919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
    Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
    Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.
    Lambert F; Heimann P; Herens C; Chariot A; Bours V
    J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
    Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
    Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
    [No Abstract]   [Full Text] [Related]  

  • 20. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.